CBD

For adults, the most defensible answer is not “CBD works” or “CBD does nothing.” The evidence is mixed, but controlled studies have not established a reliable benefit for oral CBD across pain, anxiety symptoms, or sleep concerns. Results depend heavily on whether a product contains CBD alone, THC, or several cannabinoids.

The strongest findings are also narrower than many advertisements imply. A recent sleep review found no clear benefit from CBD-only therapies, while a large pain review found no clear evidence that CBD-dominant medicines produce major pain relief. Positive reports from surveys and uncontrolled studies are useful signals, but they cannot separate CBD from expectancy, changing medications, other treatments, or natural symptom changes.[6][8][2][9]

The 2026 Cochrane review included 21 randomized studies with 2,187 adults who had chronic neuropathic pain. Five studies tested CBD-dominant medicines in 208 people. Compared with placebo, these medicines showed no clear improvement in achieving at least 50% pain relief, and the certainty of evidence was very low. The review included several cannabis-based medicines and routes, so it is broader than non-prescription oral CBD alone.

Some individual findings are more encouraging, but they are less decisive. A real-world capsule study assigned adults with fibromyalgia, rheumatoid arthritis, or osteoarthritis to three cannabinoid compositions, including CBD and CBD-acid products. Symptoms improved among those completing follow-up, but only 168 of 276 recruits completed all surveys, there was no placebo group, and the main analysis was per protocol. An online survey of 878 people with fibromyalgia who already used CBD found that many reported substituting it for medicines and feeling better, but the cross-sectional design cannot show that CBD caused those changes.[8][9]

For sleep, a 2025 meta-analysis combined six randomized trials involving 1,077 adults with or without insomnia or poor sleep. Cannabinoids as a broad category improved self-reported sleep quality, but the studies were highly inconsistent. When the analysis was limited to CBD-only therapies, the effect was small and not clearly different from placebo. This result does not prove that CBD cannot help any individual, but it does not establish a dependable sleep benefit.

Human evidence for anxiety in the supplied set is limited. In a double-blind dental trial, a CBD-rich cannabis extract did not reduce dental anxiety more than placebo, and it did not improve postoperative pain. Dental anxiety is a specific situation, so the result should not be generalized to every anxiety disorder. Conversely, it means there is not enough evidence here to claim a broad anti-anxiety effect. A registered study in adults with HIV-related neuropathic pain was designed to examine acute CBD and THC effects and longer-term real-world use, but the supplied registry record does not provide numerical results.[6][4]

Safety depends on the product and what else a person takes. In a controlled laboratory study of 31 healthy adults, CBD was combined with hydromorphone, an opioid, at several amounts. CBD changed some acute pain responses, but it did not improve laboratory chronic-pain outcomes. At the highest tested amount, 200 milligrams, participants reported more bad effects and adverse effects. This was a short laboratory study of CBD with an opioid, not proof of how CBD alone affects driving, work, or everyday alertness.

The broader pain review found nervous-system adverse events more often with THC-dominant medicines and reported very uncertain safety findings for balanced THC/CBD products. Those results cannot be assigned directly to CBD isolate. A case report of a 63-year-old woman receiving a THC:CBD extract alongside extensive multimodal care documented better pain and sleep by discharge, but also low blood-pressure readings and dry mouth. One case, especially one involving THC and many other medicines, cannot establish either safety or causation. The supplied adult evidence also does not provide a reliable estimate of liver-enzyme risk from non-prescription CBD, so a lack of a reported liver signal should not be read as proof of no risk.[5]

Clinical research studies a particular preparation, while retail products can be sold as CBD isolate, hemp extract, full-spectrum CBD, or blends containing CBD-acid and other cannabinoids. In the fibromyalgia survey, researchers separated isolate, hemp, and CBD-cannabis users, and the groups reported different substitution patterns and symptom changes. That variation makes it unsafe to transfer a result from one formulation to every bottle labeled CBD.

The evidence supplied here does not verify the strength, THC content, contaminants, or batch consistency of the broader retail market. It also does not quantify interactions with common medicines. The hydromorphone study shows that CBD can alter the effects of at least one other drug in a controlled setting, while the multimorbid case report illustrates how difficult it is to interpret oral cannabis effects when several medicines and therapies are involved. A medication review is especially important before combining CBD with drugs that affect alertness, blood pressure, or liver metabolism.[2][9]